Flibanserin: A controversial drug for female hypoactive sexual desire disorder

Sexual functioning is an integral part of human life. Female sexual dysfunction (FSD) adversely affects quality of life and general well-being. The Food and Drug Administration recently approved flibanserin, for treatment of female hypoactive sexual desire disorder (HSDD), regarded as the most commo...

Descripción completa

Detalles Bibliográficos
Autores principales: Baid, Rashmi, Agarwal, Rakesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198608/
https://www.ncbi.nlm.nih.gov/pubmed/30416308
http://dx.doi.org/10.4103/ipj.ipj_20_16
_version_ 1783365001562554368
author Baid, Rashmi
Agarwal, Rakesh
author_facet Baid, Rashmi
Agarwal, Rakesh
author_sort Baid, Rashmi
collection PubMed
description Sexual functioning is an integral part of human life. Female sexual dysfunction (FSD) adversely affects quality of life and general well-being. The Food and Drug Administration recently approved flibanserin, for treatment of female hypoactive sexual desire disorder (HSDD), regarded as the most common FSD, amid great controversy. A novel multifunctional serotonin agonist and antagonist, flibanserin, has been shown to be efficacious in treating HSDD but with a rather tenacious side effect profile. We review this interesting drug in its entirety. Data for the article were collected by reviewing articles on PubMed, the drug (Addyi) website, and related websites on the internet.
format Online
Article
Text
id pubmed-6198608
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-61986082018-11-09 Flibanserin: A controversial drug for female hypoactive sexual desire disorder Baid, Rashmi Agarwal, Rakesh Ind Psychiatry J Short Communication Sexual functioning is an integral part of human life. Female sexual dysfunction (FSD) adversely affects quality of life and general well-being. The Food and Drug Administration recently approved flibanserin, for treatment of female hypoactive sexual desire disorder (HSDD), regarded as the most common FSD, amid great controversy. A novel multifunctional serotonin agonist and antagonist, flibanserin, has been shown to be efficacious in treating HSDD but with a rather tenacious side effect profile. We review this interesting drug in its entirety. Data for the article were collected by reviewing articles on PubMed, the drug (Addyi) website, and related websites on the internet. Medknow Publications & Media Pvt Ltd 2018 /pmc/articles/PMC6198608/ /pubmed/30416308 http://dx.doi.org/10.4103/ipj.ipj_20_16 Text en Copyright: © 2018 Industrial Psychiatry Journal http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Short Communication
Baid, Rashmi
Agarwal, Rakesh
Flibanserin: A controversial drug for female hypoactive sexual desire disorder
title Flibanserin: A controversial drug for female hypoactive sexual desire disorder
title_full Flibanserin: A controversial drug for female hypoactive sexual desire disorder
title_fullStr Flibanserin: A controversial drug for female hypoactive sexual desire disorder
title_full_unstemmed Flibanserin: A controversial drug for female hypoactive sexual desire disorder
title_short Flibanserin: A controversial drug for female hypoactive sexual desire disorder
title_sort flibanserin: a controversial drug for female hypoactive sexual desire disorder
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198608/
https://www.ncbi.nlm.nih.gov/pubmed/30416308
http://dx.doi.org/10.4103/ipj.ipj_20_16
work_keys_str_mv AT baidrashmi flibanserinacontroversialdrugforfemalehypoactivesexualdesiredisorder
AT agarwalrakesh flibanserinacontroversialdrugforfemalehypoactivesexualdesiredisorder

Ejemplares similares